Sign in with Google. Opens in new tab
bullish
Paion - Progressing towards filings in US and Japan
SUMMARY
Paion and partner Cosmo took an important step towards a US filing for its ultra-short-acting sedative/anaesthetic remimazolam, with the completion of a successful pre-NDA meeting in July. Filing in Japan (via partner Mundipharma) is expected before the end of 2018. Paion took a step towards its goal of self-commercialising remimazolam in Europe with the initiation of a Phase III study in general anaesthesia (GA) in July. The company is funded beyond top-line data from the EU Phase III trial expected in 2019. We lift our valuation to €283m or €4.44 per share.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- SK Square: Time to Take Profits + Why Are There Holdco Discounts in the First Place?
- Johns Lyng (JLG AU): PEP's A$4/Share Offer Looks Light
- Ohayo Japan | Markets Climb as Nvidia, Bitcoin Soar
- KOSPI Size Indices: Overlaps Between Active & Passive Flows
- SBI Possible US$3bn QIP - Will Be One of the Largest Fund Raisings in India, Last One Didn’t Do Well
Top Unpaywalled Insights
More »- De-Dollarisation Debate : Unmasking USD Over-Valuation
- US Equities Hit All-Time Highs—but Are Markets Ignoring Growing Risks?
- Why America's Manufacturing Dreams Might Be Economic Nightmares
- Systematic Global Macro: Data, AI, and Models Are Reshaping Investing | New Barbarians AI Agent #05
- China Housing - A Mid-Year Check
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- Paion - Progressing towards filings in US and Japan13 Aug 2018
x